Estrogen is the most effective treatment for hot flashes. If you can't take it, you are not stuck. Several non-hormonal prescriptions cut hot flashes by about half. That is less than estrogen, which cuts them by about three quarters, but for many women half fewer hot flashes is the difference between sleeping through the night and not.

This is a plain guide to the three with the best evidence: venlafaxine, oxybutynin and low-dose paroxetine. One point up front, because it changes the answer for some readers: if you take tamoxifen, the choice is not free. More on that below.

How These Compare to Estrogen

The fairest comparison comes from a head-to-head trial. Venlafaxine 75 mg a day cut hot flash frequency by 48 percent, against 53 percent for low-dose estradiol. The five-point gap was not statistically significant (Joffe, JAMA Internal Medicine 2014). A pooled analysis of several trials put venlafaxine, the antidepressant escitalopram and low-dose estradiol all at roughly a 50 percent reduction, against about 30 percent for placebo (Guthrie, Obstetrics and Gynecology 2015).

Set your expectation there: a non-hormonal option will likely take you from, say, ten hot flashes a day to five, not to one. Five fewer a day is real relief, and worth being clear about up front.

Venlafaxine

Venlafaxine is an SNRI, a type of antidepressant, used off-label for hot flashes. It has the strongest track record of the non-hormonal options and works quickly for this purpose, often within one to two weeks, with the full effect by about four weeks. The dose for hot flashes is 75 mg a day, lower than many antidepressant doses, and you start at 37.5 mg for the first week.

The main things to know: it can nudge blood pressure up, so a recent reading matters. Do not stop it suddenly, because that causes dizziness and other withdrawal effects; a taper fixes that. And it is the preferred choice for women on tamoxifen, which we explain below.

Oxybutynin

Oxybutynin is normally a bladder medicine, used off-label for hot flashes. It is neither a hormone nor an antidepressant, which makes it a good fit if you would rather avoid both. In a placebo-controlled trial in women who could not take estrogen, oxybutynin at 5 mg twice a day cut weekly hot flashes by 7.5 against 2.6 for placebo (Leon-Ferre, ACCRU trial, JNCI Cancer Spectrum 2020). That puts it right alongside the antidepressants.

The trade-off is the anticholinergic effect: dry mouth is common, along with constipation. It is not used if you have narrow-angle glaucoma or trouble emptying your bladder. There is also a longer-term consideration. Large studies in older adults link high, cumulative use of anticholinergic medicines over years to a higher risk of dementia (Gray, JAMA Internal Medicine 2015). That signal comes from long-term, high-dose use in older people, not from short courses, but it is the reason to use the lowest dose that works and to avoid stacking it with other drying medicines.

Low-Dose Paroxetine

Paroxetine is an SSRI antidepressant, and at a low dose it is the one medicine the FDA has actually approved for hot flashes. It was sold as Brisdelle 7.5 mg; that brand has been discontinued, and the same drug is available as generic paroxetine. The two trials behind its approval showed a statistically significant but modest reduction over placebo (Simon, Menopause 2013). Its effect sits at the lower end of this group.

There is one firm rule with paroxetine, in the next section.

If You Take Tamoxifen, the Choice Is Not Free

Tamoxifen is a prodrug. Your liver has to convert it, using an enzyme called CYP2D6, into the active form that does the work against breast cancer. Paroxetine is a strong blocker of that enzyme. A large population study linked taking paroxetine and tamoxifen together to a higher risk of breast cancer death (Kelly, BMJ 2010), and paroxetine's own label advises considering avoiding the combination.

So if you take tamoxifen, paroxetine is off the table. Venlafaxine barely touches that enzyme and is the preferred antidepressant for hot flashes in women on tamoxifen (Desmarais, Journal of Clinical Psychiatry 2009). Oxybutynin is fine too, since it does not work through that enzyme. Aromatase inhibitors, the other common breast cancer pill, do not depend on CYP2D6, so all three are acceptable if you take one of those instead. If you are not sure which breast cancer medicine you are on, that is worth pinning down before choosing.

We cover this in more depth in hot flashes after breast cancer.

What About Veozah and Lynkuet?

Two newer non-hormonal drugs target the brain's temperature center directly. Fezolinetant (Veozah) is FDA-approved and works well, but it carries a boxed warning for liver injury and needs repeated blood tests, which does not fit an online model. Elinzanetant (Lynkuet), approved in October 2025, has the cleanest evidence in women on breast cancer treatment but is brand-only at over 600 dollars a month, with savings programs that do not reach people paying cash. They are real options to discuss with an in-person clinician; they are not a fit for a low-cost online service yet.

The Short Version

Venlafaxine and oxybutynin both cut hot flashes by about half, are cheap generics, are safe with tamoxifen and need no routine blood tests. Low-dose paroxetine is FDA-approved and reasonable, except with tamoxifen. Estrogen is still more effective if you can take it, and hormone therapy is worth a look if nothing rules it out.

Reviewed By

[Reviewed by: clinician name, credential. Last reviewed: date.]

Can't take estrogen, or would rather not? See the non-hormonal options and start an intake. A licensed clinician will review it and, if you ask, choose the safest fit for you.

This article is for education and is not a substitute for individual medical advice from your own clinician.